Cargando…

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma

BACKGROUND: The biological understanding of glioblastoma (GB) with gliomatosis cerebri (GC) pattern is poor due to the absence of GC-specific studies. Here, we aimed to identify molecular or clinical parameters that drive GC growth. METHODS: From our methylome database of IDH (isocitrate dehydrogena...

Descripción completa

Detalles Bibliográficos
Autores principales: Divé, Iris, Weber, Katharina J, Hartung, Tabea I, Steidl, Eike, Wagner, Marlies, Hattingen, Elke, Franz, Kea, Fokas, Emmanouil, Ronellenfitsch, Michael W, Herrlinger, Ulrich, Harter, Patrick N, Steinbach, Joachim P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676054/
https://www.ncbi.nlm.nih.gov/pubmed/38024242
http://dx.doi.org/10.1093/noajnl/vdad131
_version_ 1785141204650819584
author Divé, Iris
Weber, Katharina J
Hartung, Tabea I
Steidl, Eike
Wagner, Marlies
Hattingen, Elke
Franz, Kea
Fokas, Emmanouil
Ronellenfitsch, Michael W
Herrlinger, Ulrich
Harter, Patrick N
Steinbach, Joachim P
author_facet Divé, Iris
Weber, Katharina J
Hartung, Tabea I
Steidl, Eike
Wagner, Marlies
Hattingen, Elke
Franz, Kea
Fokas, Emmanouil
Ronellenfitsch, Michael W
Herrlinger, Ulrich
Harter, Patrick N
Steinbach, Joachim P
author_sort Divé, Iris
collection PubMed
description BACKGROUND: The biological understanding of glioblastoma (GB) with gliomatosis cerebri (GC) pattern is poor due to the absence of GC-specific studies. Here, we aimed to identify molecular or clinical parameters that drive GC growth. METHODS: From our methylome database of IDH (isocitrate dehydrogenase)-wildtype GB, we identified 158 non-GC and 65 GC cases. GC cases were subdivided into diffuse-infiltrative (subtype 1), multifocal (subtype 2), or tumors with 1 solid mass (subtype 3). We compared clinical, histological, and molecular parameters and conducted a reference-free tumor deconvolution of DNA methylation data based on latent methylation components (LMC). RESULTS: GC subtype 1 less frequently showed contrast-enhancing tumors, and more frequently lacked morphological GB criteria despite displaying GB DNA methylation profile. However, the tumor deconvolution did not deliver a specific LMC cluster for either of the GC subtypes. Employing the reference-based analysis MethylCIBERSORT, we did not identify significant differences in tumor cell composition. The majority of both GC and non-GC patients received radiochemotherapy as first-line treatment, but there was a major imbalance for resection. The entire GC cohort had significantly shorter overall survival (OS) and time to treatment failure (TTF) than the non-GC cohort. However, when filtering for cases in which only stereotactic biopsy was performed, the comparison of OS and TTF lost statistical significance. CONCLUSIONS: Our study offers clinically relevant information by demonstrating a similar outcome for GB with GC growth pattern in the surgically matched analysis. The limited number of cases in the GC subgroups encourages the validation of our DNA methylation analysis in larger cohorts.
format Online
Article
Text
id pubmed-10676054
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106760542023-10-17 Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma Divé, Iris Weber, Katharina J Hartung, Tabea I Steidl, Eike Wagner, Marlies Hattingen, Elke Franz, Kea Fokas, Emmanouil Ronellenfitsch, Michael W Herrlinger, Ulrich Harter, Patrick N Steinbach, Joachim P Neurooncol Adv Clinical Investigations BACKGROUND: The biological understanding of glioblastoma (GB) with gliomatosis cerebri (GC) pattern is poor due to the absence of GC-specific studies. Here, we aimed to identify molecular or clinical parameters that drive GC growth. METHODS: From our methylome database of IDH (isocitrate dehydrogenase)-wildtype GB, we identified 158 non-GC and 65 GC cases. GC cases were subdivided into diffuse-infiltrative (subtype 1), multifocal (subtype 2), or tumors with 1 solid mass (subtype 3). We compared clinical, histological, and molecular parameters and conducted a reference-free tumor deconvolution of DNA methylation data based on latent methylation components (LMC). RESULTS: GC subtype 1 less frequently showed contrast-enhancing tumors, and more frequently lacked morphological GB criteria despite displaying GB DNA methylation profile. However, the tumor deconvolution did not deliver a specific LMC cluster for either of the GC subtypes. Employing the reference-based analysis MethylCIBERSORT, we did not identify significant differences in tumor cell composition. The majority of both GC and non-GC patients received radiochemotherapy as first-line treatment, but there was a major imbalance for resection. The entire GC cohort had significantly shorter overall survival (OS) and time to treatment failure (TTF) than the non-GC cohort. However, when filtering for cases in which only stereotactic biopsy was performed, the comparison of OS and TTF lost statistical significance. CONCLUSIONS: Our study offers clinically relevant information by demonstrating a similar outcome for GB with GC growth pattern in the surgically matched analysis. The limited number of cases in the GC subgroups encourages the validation of our DNA methylation analysis in larger cohorts. Oxford University Press 2023-10-17 /pmc/articles/PMC10676054/ /pubmed/38024242 http://dx.doi.org/10.1093/noajnl/vdad131 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Investigations
Divé, Iris
Weber, Katharina J
Hartung, Tabea I
Steidl, Eike
Wagner, Marlies
Hattingen, Elke
Franz, Kea
Fokas, Emmanouil
Ronellenfitsch, Michael W
Herrlinger, Ulrich
Harter, Patrick N
Steinbach, Joachim P
Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
title Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
title_full Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
title_fullStr Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
title_full_unstemmed Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
title_short Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
title_sort gliomatosis cerebri (gc) growth pattern: a single-center analysis of clinical, histological, and molecular characteristics of gc and non-gc glioblastoma
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676054/
https://www.ncbi.nlm.nih.gov/pubmed/38024242
http://dx.doi.org/10.1093/noajnl/vdad131
work_keys_str_mv AT diveiris gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT weberkatharinaj gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT hartungtabeai gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT steidleike gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT wagnermarlies gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT hattingenelke gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT franzkea gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT fokasemmanouil gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT ronellenfitschmichaelw gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT herrlingerulrich gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT harterpatrickn gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma
AT steinbachjoachimp gliomatosiscerebrigcgrowthpatternasinglecenteranalysisofclinicalhistologicalandmolecularcharacteristicsofgcandnongcglioblastoma